96 related articles for article (PubMed ID: 27317994)
1. Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Lippi G; Sanchis-Gomar F
Int J Cardiol; 2016 Sep; 219():111-4. PubMed ID: 27317994
[TBL] [Abstract][Full Text] [Related]
2. Natriuretic peptide family as diagnostic/prognostic biomarker and treatment modality in management of adult and geriatric patients with heart failure: remaining issues and challenges.
Zhang ZL; Li R; Yang FY; Xi L
J Geriatr Cardiol; 2018 Aug; 15(8):540-546. PubMed ID: 30344534
[TBL] [Abstract][Full Text] [Related]
3. MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts.
Nakagawa Y; Nishikimi T; Kuwahara K; Fujishima A; Oka S; Tsutamoto T; Kinoshita H; Nakao K; Cho K; Inazumi H; Okamoto H; Nishida M; Kato T; Fukushima H; Yamashita JK; Wijnen WJ; Creemers EE; Kangawa K; Minamino N; Nakao K; Kimura T
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28188250
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in natriuretic peptide research.
Woodard GE; Rosado JA
J Cell Mol Med; 2007; 11(6):1263-71. PubMed ID: 18205700
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
Tsutsui H; Albert NM; Coats AJS; Anker SD; Bayes-Genis A; Butler J; Chioncel O; Defilippi CR; Drazner MH; Felker GM; Filippatos G; Fiuzat M; Ide T; Januzzi JL; Kinugawa K; Kuwahara K; Matsue Y; Mentz RJ; Metra M; Pandey A; Rosano G; Saito Y; Sakata Y; Sato N; Seferovic PM; Teerlink J; Yamamoto K; Yoshimura M
Eur J Heart Fail; 2023 May; 25(5):616-631. PubMed ID: 37098791
[TBL] [Abstract][Full Text] [Related]
6. Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure.
Raizada A; Bhandari S; Khan MA; Singh HV; Thomas S; Sarabhai V; Singh N; Trehan N
Indian J Clin Biochem; 2007 Mar; 22(1):4-9. PubMed ID: 23105644
[TBL] [Abstract][Full Text] [Related]
7. Endogenous B-type natriuretic peptide: a limb of the regulatory response to acutely decompensated heart failure.
Hobbs RE; Mills RM
Clin Cardiol; 2008 Sep; 31(9):407-12. PubMed ID: 18781599
[TBL] [Abstract][Full Text] [Related]
8. Clinical markers in heart failure: a narrative review.
Javed N; El-Far M; Vittorio TJ
J Int Med Res; 2024 May; 52(5):3000605241254330. PubMed ID: 38779976
[TBL] [Abstract][Full Text] [Related]
9. Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.
Lanfear DE; Chow S; Padhukasahasram B; Li J; Langholz D; Tang WH; Williams LK; Sabbah HN
J Card Fail; 2014 Sep; 20(9):662-8. PubMed ID: 24983826
[TBL] [Abstract][Full Text] [Related]
10. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.
Hawkridge AM; Heublein DM; Bergen HR; Cataliotti A; Burnett JC; Muddiman DC
Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17442-7. PubMed ID: 16293687
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis.
Prokopidis K; Morwani-Mangnani J; McDowell G; Lip GYH; Venturelli M; Sankaranarayanan R; Isanejad M
Eur Geriatr Med; 2024 Mar; ():. PubMed ID: 38457043
[TBL] [Abstract][Full Text] [Related]
12. B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor.
Harpaz D; Seet RCS; Marks RS; Tok AIY
Biosensors (Basel); 2020 Aug; 10(9):. PubMed ID: 32859068
[TBL] [Abstract][Full Text] [Related]
13. Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.
Lee NS; Daniels LB
Card Fail Rev; 2016 May; 2(1):14-19. PubMed ID: 28848655
[TBL] [Abstract][Full Text] [Related]
14. Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Liczek M; Panek I; Damiański P; Jęczeń O; Jaźwiec J; Kuna P; Panek M
Adv Respir Med; 2018 Aug; ():. PubMed ID: 30110121
[TBL] [Abstract][Full Text] [Related]
15. Neprilysin and Corin in HF: Does Combining 2 Biomarkers Double Our Insights?
Gladysheva IP; Sullivan RD; Reed GL
JACC Heart Fail; 2021 May; 9(5):406. PubMed ID: 33926738
[No Abstract] [Full Text] [Related]
16. Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
Ramanathan K; Padmanabhan G
Indian Heart J; 2020; 72(1):14-19. PubMed ID: 32423555
[TBL] [Abstract][Full Text] [Related]
17. Retracted: The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9850396. PubMed ID: 38094326
[TBL] [Abstract][Full Text] [Related]
18. Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin.
Chen HH; Burnett JC
JACC Basic Transl Sci; 2020 Jul; 5(7):727-729. PubMed ID: 32760917
[TBL] [Abstract][Full Text] [Related]
19. BNP and Precision Medicine: Tip of an Iceberg.
Lanfear DE; Luzum JA
JACC Basic Transl Sci; 2021 Jun; 6(6):505-506. PubMed ID: 34222721
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
